Unicycive Gains FDA Acceptance for OLC NDA Resubmission

Unicycive Therapeutics' path to approval for oxylanthanum carbonate (OLC) now runs through a new drug product manufacturer, a structural shift in CMC strategy that carries direct implications for pre-approval inspection planning and third-party vendor qualification. The FDA accepted the NDA resubmission on October 21, 2026, assigning a Class II review designation and a PDUFA target action date of March 25, 2027.

The resubmission follows a second Complete Response Letter issued in June 2026, in which the FDA cited unresolved manufacturing deficiencies at the original third-party drug product facility, a site the agency had been unable to re-inspect during the prior review cycle. Rather than await re-inspection of that facility, Unicycive pivoted to a new contract manufacturer whose site received a No Action Indicated outcome at its most recent FDA inspection in March 2024.

For QA directors and plant heads, the case surfaces a recurring tension in CRL remediation: the risk calculus of retaining a flagged CMC vendor versus the timeline cost of qualifying a replacement. Unicycive's resubmission now includes CMC data generated at the new facility, but the company has disclosed it does not yet know whether FDA will conduct a pre-approval inspection of that site ahead of the March 2027 action date.

A parallel contingency remains open. If the original third-party manufacturer is inspected and achieves cGMP compliance before the PDUFA date, Unicycive has indicated it will seek FDA alignment on an accelerated approval timeline. That scenario depends entirely on FDA inspection scheduling, a variable outside the sponsor's control and one that regulatory affairs leads should monitor closely given its potential to compress the review window.

The underlying clinical and preclinical data package has not been a source of agency concern. FDA raised no objections to OLC's safety, efficacy, or tolerability data across three completed studies, including a Phase 1 study, a bioequivalence study, and a CKD dialysis population tolerability study. The NDA proceeds under the 505(b)(2) regulatory pathway, with the CMC remediation representing the sole outstanding deficiency category from prior submissions.

OLC is an oral phosphate binder developed for hyperphosphatemia management in chronic kidney disease patients on dialysis, a condition affecting more than 450,000 individuals annually in the United States who require pharmacological phosphate control.

The March 25, 2027 PDUFA date sets a firm checkpoint against which both pre-approval inspection outcomes and any vendor compliance developments will be measured.

Source: Unicycive Therapeutics, Inc. via GlobeNewswire, October 21, 2026.